Industry Insights

Deep dives on clinical endpoints, regulatory trends and data quality — written and curated by the EClinCloud team.

Football video review used as an analogy for independent imaging reviewInsight3 min readWhy decisive imaging endpoints need an independent second lookWhat independent central imaging review adds to multicenter trials, when sponsors should introduce IRC, and how a connected platform keeps imaging endpoints reliable.Cover image for the archived article "What Changed in the 2026 GCP? Understanding the Digital Thread Behind the Regulatory Upgrade"Insight5 min readWhat Changed in the 2026 GCP? Understanding the Digital Thread Behind the Regulatory UpgradeOn June 8, 2026, the 2026 revised GCP was jointly issued by four ministries and commissions, taking effect on September 1 and marking the full alignment of China's clinical trial regulation with ICH E6(R3).Infographic | What Regulatory Signals Does the FDA's Push for Real-Time Clinical Trials Send? — Archive article coverInsight5 min readVisual Guide | What Regulatory Signal Is the FDA Sending with Real-Time Clinical Trials?In April 2026, the FDA announced the launch of its Real-Time Clinical Trials (RTCT) pilot. On the surface, this looks like a regulatory process optimization; however, viewed alongside the FDA's recently introduced HALO unified data platform and Elsa AI system, a deeper shift is underway:Illustration for an overview of ICH E6(R3)Insight3 min readICH E6(R3): Clinical trials enter the era of risk-driven digital governanceWhat ICH E6(R3) changes for digital trial technology, risk-based quality management, data governance, and the systems sponsors use to keep evidence reliable.Archived article cover: Are You Using EClinCloud's AI-Driven EDC for Your IIT Management?Insight2 min readAre You Using EClinCloud's AI-Driven EDC for Your IIT Management?Recently, we have frequently received questions from different users about the service scope of EClinCloud's digital products. Does EClinCloud only provide digital products and services for registrational clinical trial projects for innovative pharmaceutical companies/CROs?Phase 3 Success, Yet Rejected by the FDA: Lessons for Clinical Endpoint Assessment — archived article coverInsight3 min readPhase 3 Success, Yet Rejected by the FDA: Lessons for Clinical Endpoint AssessmentIn new drug development, every subtle shift in regulatory direction reverberates across the industry. EClinCloud closely tracks global drug review trends and evolving regulatory perspectives to deliver more reliable clinical endpoint assessment solutions.Illustration for FDA clinical outcome assessment guidanceInsight3 min readFrom regulatory intent to practice: choosing a fit-for-purpose clinical outcome assessmentA practical overview of FDA PFDD Guidance 3, the four COA types, fit-for-purpose evidence, and how eCOA supports patient-focused endpoint implementation.EClinCloud at SCDM Presentation Recap | Maintaining the Blind and Approaches in RTSM Systems — archived article coverInsight1 min readEClinCloud at SCDM Presentation Recap | Maintaining Blinding and Approaches in RTSM SystemsRecently, the 8th Annual Clinical Data Management Conference (2025 SCDM) was held in Shanghai. EClinCloud was invited to give a presentation titled "Maintaining Blinding and Approaches in RTSM Systems," offering an in-depth discussion of blinding challenges in clinical research, regulatory requirements, and practical experience in implementing RTSM systems, which received broad attention and positive feedback from attendees.Latest CDE Technical Guideline for AD Drug Clinical Trials: Key Changes Explained — Archived Article CoverInsight2 min readCDE's Latest Technical Guidance for AD Drug Clinical Trials: Key Changes ExplainedIn May 2025, CDE issued the "Technical Guidance for Clinical Trials of Drugs for Alzheimer's Disease (Trial)," revising and adjusting the draft for comment released in September of the previous year and setting forth new technical requirements for Alzheimer's disease (AD) drug development. We analyzed and compared the two guidance documents. Let's take a look at the adjustments.Blinding challenges: How does an RTSM randomization system effectively address them? Archived article coverInsight2 min readBlinding Challenges: How Does an RTSM Randomization System Address Them?Blinding is a key strategy for ensuring accurate and reliable clinical study results. Its purpose is to keep both researchers and patients unaware of the specific treatment a trial participant receives, thereby controlling potential study bias. In practice, however, blinding faces numerous challenges, such as drug dispensing, inventory control, and visit scheduling. Today we share how the EClinCloud RTSM (Randomization and Trial Supply Management) system implements blinding in projects.International Application Practice | Archived article cover on EClinCloud eCOA supporting international multicenter studiesInsight2 min readGlobal Application Practice | EClinCloud eCOA Supports International Multicenter StudiesWith extensive experience and leading technology, the EClinCloud eCOA solution is supporting a growing number of international multicenter clinical trials and further improving study efficiency.From Documents to Data: How Does eTMF Reshape Clinical Trial Management? (archived article cover)Insight3 min readFrom Documents to Data: How Does eTMF Reshape Clinical Trial Management?With accelerating globalization, intensifying competition in new drug R&D, and rapid advances in AI, the digital transformation of clinical trials has increasingly become a focal point for the industry and investors.